8-K current report · filed Oct 6, 2026

Regeneron Pharmaceuticals (REGN) 8-K Current Report: October 6, 2026

Item 1.01Item 8.01Item 2.02REGN overview

Short answer

Regeneron Pharmaceuticals (REGN) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item 2.02 (Results of Operations and Financial Condition). New collaboration covers four Regeneron-invented long-acting antibodies targeting IL-13, IL-4, IL-4Rα and IL-4xIL-13.

Regeneron Pharmaceuticals 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • New collaboration covers four Regeneron-invented long-acting antibodies targeting IL-13, IL-4, IL-4Rα and IL-4xIL-13
  • Sanofi upfront payment: $1.0 billion, plus up to $7.0 billion in development, regulatory and commercial milestones
  • Global profits shared equally, while development costs are shared equally between Regeneron and Sanofi
  • Regeneron bears New Licensed Products development costs above budget caps, subject to future recoupment rights
  • Regeneron leads pre-approval development and U.S. regulatory work, while Sanofi leads ex-U.S. commercialization

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 GAAP and non-GAAP results expected to include approximately $22 million pre-tax acquired IPR&D charge
  • Acquired IPR&D expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.18
  • Charge reflects collaboration, licensing or asset-acquisition investment, signaling continued pipeline development spending
  • Preliminary unaudited estimates remain subject to financial close and potential revision

Item 8.01 · Other Events

  • Settlement resolves Regeneron’s lawsuit against Sanofi over Dupixent commercialization information access and audit rights
  • Sixth Amendment remains the governing agreement, with expected payments and new licensed products affecting future economics
  • Expected acquired in-process R&D charge for quarter ended September 30, 2026, potentially reducing GAAP and non-GAAP diluted EPS
  • Investors should monitor the Sixth Amendment’s payment terms and commercialization milestones, referenced elsewhere in the filing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Regeneron Pharmaceuticals 8-K filings

Get the next REGN 8-K as it lands

Follow REGN for push alerts, or ask the research agent what this filing means.